Daniel Griffin provides a clinical report on COVID-19, then we discuss decline of virus-specific bone marrow B cells within a year after influenza vaccination, the push to release SARS-CoV-2 vaccines before completion of phase 3 trials, and absence of evidence for infectious virus in aerosols.
Click arrow to play
Download TWiV 660 (95 MB .mp3, 159 min)
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Show notes at microbe.tv/twiv
2 thoughts on “TWiV 660: In case of emergency finish the trial”
I have to disagree with you vehemently on this one Vincent. The plausible deaths or side effects caused by any vaccine in process are not remotely near the certain deaths and economic effects of this virus. The numbers are so extreme it’s completely insane to dot all those i’s and cross all those t’s while Rome figuratively burns.
Here’s a peer published editorial on this that also brings into focus the reality that we will be dealing with biological weapons in the future. Had this been a real weapon, we could have lost the nation. It’s quite simply insanity to keep on this track in the face of pandemics. We should have released vaccines in March, with tracking in phase IV.
Comments are closed.